Bigfoot Biomedical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bigfoot Biomedical, Inc.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.
Dexcom’s CEO explained the company’s strategy for continued growth, including marketing opportunities for its G6 and G6 Pro continuous glucose monitors and plans for the next-gen G7 CGM.
Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.
- Drug Delivery
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
- Asante Solutions, Inc.
- Patients Pending Ltd